

Current - Trial Demographics					
Trial Name	Indication	Drug/Device	Sponsor/CRO/IRB	PI/SC	Trial Description
AEGIS ◊	ACS	CSL112	CSL Behring	Purow/Angel	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
ARTESIA ▲	A-Fib w/ICD	Apixaban	Hamilton Health Sciences	Anand/Angel	Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation
CAPACITY ▲	HFpEF	IW-1973	Ironwood Pharmaceuticals	Larned/Mara-Li	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction
CONNECT ▲	HFREF	Outcomes Registry	Duke	Larned/Mara-Li	Care Optimization through patient and hospital engagement clinical trial for heart failure. Outcomes will be assessed in the year following discharge for participants
CORVIA REDUCE Lap-HF ▲	CHF	Device	Corvia Med	Larned/Angel	Evaluate the Corvia Medical, Inc. IASD System II to improve the quality of life and reduce heart failure related symptoms and events in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF) with elevated left atrial pressures, who remain symptomatic despite optimal GDMT
ESPERION CVD ▲	CVD	Interventional	Esperion Therapeutics	Russo/Donovan	A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant
TRANSFORM ▲	HFREF	torseamide vs. furosemide	DCRI	Larned/Donovan	To compare torsemide versus furosemide on long-term clinical outcomes among patients hospitalized for heart failure.
VICTORIA HF ▲	HF	Vericiguat	Merck	Larned/Angel	A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFREF) - VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction
ZOLL HEARIT – HF ▲	ICD	Observational	ZOLL	Larned/Angel	Heart Sounds for Heart Failure Management in Patients Using the Wearable Cardioverter Defibrillator (HEARIT-HF) Study the population for this study will be adult patients with documented HF during the index hospitalization, EF < 35% and eligible to wear the WCD for at least 3 months.

◊ Enrollment Pending Ω Closed to Enrollment ▲ Enrolling » Site Closure

CONTACT: Holy Cross Heart & Vascular Research Institute 954-229-8400



Contact Information
Angel Lescay 954-267-6792 Angel.Lescay@holy-cross.com or Christine Lepurage 954-229-8571 Christine.Lepurage@holy-cross.com
Grey Sanchez 954-229-8572 Sanchez.Grey @holy-cross.com or Angel Lescay 954-267-6792 Angel.Lescay@holy-cross.com
Mara-Li Ortiz 954-229-8552 Mara-Li.Ortiz@holy-cross.com or Donovan Mott 954-229-8571 Donovan.Mott@holy-cross.com
Mara-Li Ortiz 954-229-8552 Mara-Li.Ortiz@holy-cross.com or Donovan Mott 954-229-8571 Donovan.Mott@holy-cross.com
Angel Lescay 954-267-6792 Angel.Lescay@holy-cross.com or Christine Lepurage 954-229-8571 Christine.Lepurage@holy-cross.com
Donovan Mott 954-229-8571 Donovan.Mott@holy-cross.com or Grey Sanchez 954-229-8575 Sanchez.Grey@holy-cross.com
Donovan Mott 954-229-8571 Donovan.Mott@holy-cross.com or Mara-Li Ortiz 954-229-8552 Mara-Li.Ortiz@holy-cross.com
Angel Lescay 954-267-6792 Angel.Lescay@holy-cross.com or Mara-Li Ortiz 954-229-8552 Mara-Li.Ortiz@holy-cross.com
Angel Lescay 954-267-6792 Angel.Lescay@holy-cross.com or Christine Lepurage 954-229-8571 Christine.Lepurage@holy-cross.com